Abstract:Genetic diseases affecting the retina can result in partial or complete loss of visual function. Leber's Congenital Amaurosis (LCA) is a rare blinding disease, usually inherited in an autosomally recessive manner, with no cure. Retinal gene therapy has been shown to improve vision in LCA patients caused by mutations in the RPE65 gene (LCA2). However, little is known about how activity in central visual pathways is affected by the disease or by subsequent gene therapy. Functional MRI was used to assess retinal signal transmission in cortical and subcortical visual structures before and one year after retinal intervention. The fMRI paradigm consisted of 15-second blocks of flickering (8-Hz) black and white checkerboards interleaved with 15 seconds of blank (black) screen. Visual activation in the brain was assessed using the general linear model, with multiple comparisons corrected using the false discovery rate method. Response to visual stimulation through untreated eyes of LCA2 patients showed heightened fMRI responses in the superior colliculus (SC) and diminished activities in the lateral geniculate nucleus (LGN) compared to controls, indicating a shift in the patients' visual processing towards the retinotectal pathway (RT). Following gene therapy, stimuli presented to the treated eye elicited significantly stronger fMRI responses in the LGN and primary visual cortex, indicating some reengagement of the geniculostriate pathway (GS) pathway. Across patients, the post-treatment LGN fMRI responses correlated significantly with performance on a clinical test measuring light sensitivity. Our results demonstrate that the low vision observed in LCA2 patients involves a shift in visual processing toward the retinotectal pathway, and that gene therapy partially reinstates visual transmission through the GS pathway. This selective boosting of retinal output through the GS pathway and its correlation to improved visual performance, following several years of degenerative retinal disease, is striking. However, while retinal gene therapy and other ocular interventions have given hope to RPE65 patients, it may take years before development of therapies tailored to treat the diseases in other low vision patients are available. Our demonstration of a shift toward the RT pathway in these patients may spur the development of new tools and rehabilitation strategies to help maximize the use of residual visual abilities and augment experience-dependent plasticity.

Gene Therapy of Dominant CRX-Leber Congenital Amaurosis using Patient Stem Cell-Derived Retinal Organoids

Abnormal morphology and function in retinal ganglion cells derived from patients-specific iPSCs generated from individuals with Leber's hereditary optic neuropathy.

AAV-mediated gene augmentation therapy of CRB1 patient-derived retinal organoids restores the histological and transcriptional retinal phenotype

Generation and Characterization of Induced Pluripotent Stem Cells and Retinal Organoids from a Leber's Congenital Amaurosis Patient with Novel RPE65 Mutations.

Gene Therapy Rescues Cone Structure and Function in the 3-Month-oldrd12mouse: A Model for Midcourse RPE65 Leber Congenital Amaurosis

Effective AAV-mediated gene replacement therapy in retinal organoids modelling AIPL1-associated LCA4

Unlocking therapeutic potential: dual gene therapy for ameliorating the disease phenotypes in a mouse model of RPE65 Leber congenital amaurosis

Gene augmentation therapy to rescue degenerative photoreceptors in a Cwc27 mutant mouse model

Retinal Organoids with X-linked Retinoschisis RS1 (E72K) Mutation Exhibit a Photoreceptor Developmental Delay and Are Rescued by Gene Augmentation Therapy.

Dual CRALBP isoforms unveiled: iPSC-derived retinal modelling and AAV2/5-RLBP1 gene transfer raise considerations for effective therapy

CRX haploinsufficiency compromises photoreceptor precursor translocation and differentiation in human retinal organoids

Differential Proteomics And Functional Research Following Gene Therapy In A Mouse Model Of Leber Congenital Amaurosis

RNAi-mediated Gene Suppression in a GCAP1(L151F) Cone-Rod Dystrophy Mouse Model.

Extended functional rescue following AAV gene therapy in a canine model of LRIT3-congenital stationary night blindness

Investigating Cone Photoreceptor Development Using Patient-Derived Nrl Null Retinal Organoids

RNA Interference Gene Therapy in Dominant Retinitis Pigmentosa and Cone-Rod Dystrophy Mouse Models Caused by GCAP1 Mutations

Toward the Treatment of Inherited Diseases of the Retina Using CRISPR-Based Gene Editing

Gene Correction Reverses Ciliopathy and Photoreceptor Loss in Ipsc-Derived Retinal Organoids from Retinitis Pigmentosa Patients

Central visual pathways affected by degenerative retinal disease before and after gene therapy

Generation of Nonhuman Primate Model of Cone Dysfunction Through in Situ AAV-Mediated CNGB3 Ablation

CRISPR/SaCas9-based gene editing rescues photoreceptor degeneration throughout a rhodopsin-associated autosomal dominant retinitis pigmentosa mouse model